Actavis

Abbvie’s $63 billion approach for Allergan is just the latest episode in what can be a generally bewildering cycle of making and remaking of businesse(...)

Customs are intercepting and seizing large amounts of a revolutionary anti- HIV drug which is being ordered by people online. Pre-Exposure Proph(...)

Profits at Ireland’s Top 1000 companies roared to a record high of some €36 billion in the 2016 survey, as the country’s top companies shrugged off t(...)

Foreign direct investment (FDI) among top industrial countries almost doubled last year with large inflows recorded in Ireland, the Netherlands, Switz(...)

The US government has taken steps to crack down further on tax-avoiding corporate “inversion” deals involving American corporations merging with overs(...)

A spate of so-called “tax inversion” deals involving companies based in Ireland appears to be distorting the country’s foreign direct investment (FDI(...)

A survey has found that Seagate Technology, an American data storage company, is the single biggest investor in research and development (R&D) in(...)

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Keeping track of the merry-go-round that is pharma M&A is quite a challenge. It’s not all down to corporate inversion – that bête noir of US polit(...)